These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38253223)

  • 1. Evaluation of a Novel LC-MS/MS Based Analytical Method for the Risk Assessment of Nitrosamines in Pharmaceutical Products and Packaging Materials.
    Kartop RA; Güleli M; Faruzlu FA; Çalışkan C
    J Pharm Sci; 2024 Jun; 113(6):1597-1606. PubMed ID: 38253223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A GC-MS/MS Method for Trace Level Quantification of Six Nitrosamine Impurities (NDMA, NDEA, NEIPA, NDIPA, NDPA, and NDBA) in Commercially Used Organic Solvents: Dichloromethane, Ethyl Acetate, Toluene, and O-xylene.
    Kosuri ER; Bhanti M; Jaywant MA; Han M; Wang X; Obeng M
    J Pharm Sci; 2023 May; 112(5):1225-1230. PubMed ID: 36462706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of genotoxic N-nitrosamines in active pharmaceutical ingredients and market authorized products in low abundance by means of liquid chromatography - tandem mass spectrometry.
    Vogel M; Norwig J
    J Pharm Biomed Anal; 2022 Sep; 219():114910. PubMed ID: 35779354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Performance Liquid Chromatography-Tandem Mass Spectrometry Method Development and Validation for Simultaneous Determination of Seven Nitrosamine and Azidomethyl-Biphenyl-Tetrazole Impurities in Losartan.
    Luan NM; Khuyen VTK; Tuan ND
    J Sep Sci; 2024 Oct; 47(19):e202400277. PubMed ID: 39385440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multianalyte LC-MS/MS method for accurate quantification of Nitrosamines in Olmesartan tablets.
    Pawar N; Bhardwaj A; Vora A; Sharma S
    J Chromatogr A; 2024 Sep; 1732():465176. PubMed ID: 39088899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The contamination of valsartan and other sartans, part 1: New findings.
    Sörgel F; Kinzig M; Abdel-Tawab M; Bidmon C; Schreiber A; Ermel S; Wohlfart J; Besa A; Scherf-Clavel O; Holzgrabe U
    J Pharm Biomed Anal; 2019 Aug; 172():395-405. PubMed ID: 31122801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of Carcinogenic Impurities of N-Nitrosamines in Sartan Pharmaceutical Products Marketed in Brazil: Development and Validation of Method Based on High-Performance Liquid Chromatography-Tandem Mass Spectrometry.
    Monteiro MA; de Lima PC; Novotny TS; Santana DS; Lima MED; Dantas ASCL; Ferreira LODS; de Souza MN; Maranho RLDN; Ochs SM
    J Pharm Sci; 2023 May; 112(5):1305-1314. PubMed ID: 36657719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous determination of low molecular weight nitrosamines in pharmaceutical products by fast gas chromatography mass spectrometry.
    Kalauz A; Tiringer KV; Horváth V; Kapui I
    J Chromatogr A; 2023 Oct; 1708():464323. PubMed ID: 37696123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Full Evaporation Static Headspace Gas Chromatography Method with Nitrogen Phosphorous Detection for Ultrasensitive Analysis of Semi-volatile Nitrosamines in Pharmaceutical Products.
    Zheng J; Kirkpatrick CL; Lee D; Han X; Martinez AI; Gallagher K; Evans RK; Mudur SV; Liang X; Drake J; Buhler LA; Mowery MD
    AAPS J; 2022 Jan; 24(1):23. PubMed ID: 34993666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Creating a Holistic Extractables and Leachables (E&L) Program for Biotechnology Products.
    Li K; Rogers G; Nashed-Samuel Y; Lee H; Mire-Sluis A; Cherney B; Forster R; Yeh P; Markovic I
    PDA J Pharm Sci Technol; 2015; 69(5):590-619. PubMed ID: 26429108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analytical Method Capable of Quantifying Eight Nitrosamine Impurities from Five Different Commercially Available Metformin Formulations with Glipizide, Glibenclamide, Gliclazide, Evogliptin, and Glimepiride by Ultra High Performance Liquid Chromatography Tripple Quadrupole Mass Spectrometry.
    Solanki R; Wadhwana P; Patel R; Gayakvad B; Kothari C; Patel C
    J Pharm Sci; 2023 May; 112(5):1268-1276. PubMed ID: 36822274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nitrosamine Impurities in Pharmaceuticals: An Empirical Review of their Detection, Mechanisms, and Regulatory Approaches.
    Bhirud D; Agrawal G; Shah H; Patel A; Palkar MB; Bhattacharya S; Prajapati BG
    Curr Top Med Chem; 2024; 24(6):503-522. PubMed ID: 38321910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Multi-Analyte LC-MS/MS Method for Determination and Quantification of Six Nitrosamine Impurities in Sartans like Azilsartan, Valsartan, Telmisartan, Olmesartan, Losartan and Irbesartan.
    Gopireddy RR; Maruthapillai A; Mahapatra S
    J Chromatogr Sci; 2024 Feb; 62(2):147-167. PubMed ID: 35830866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the Risk of Nitrosamine Contamination During Drug Product Blister Packaging.
    Zheng J; Brookes A; Moser J; Pfeffer H; Smith A
    J Pharm Sci; 2023 Sep; 112(9):2321-2325. PubMed ID: 37478970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Sensitive Screening Method for Simultaneous Determination of Nine Genotoxic Nitrosamines in Active Pharmaceutical Ingredients by GC-MS.
    Witkowska AB; Giebułtowicz J; Dąbrowska M; Stolarczyk EU
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36292981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LC-MS/MS Investigation of nitrosamine impurities in certain Sartan group medicinal products available in Istanbul, Türkiye.
    Öncü T; Yüksel B; Binay E; Şen N
    Ann Pharm Fr; 2024 Jan; 82(1):72-83. PubMed ID: 37567559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of an Adduct Impurity of an Active Pharmaceutical Ingredient and a Leachable in an Ophthalmic Drug Product Using LC-QTOF.
    Gollapalli R; Singh G; Blinder A; Brittin J; Sengupta A; Mondal B; Patel M; Pati B; Lee J; Ghode A; Kote M
    J Pharm Sci; 2019 Oct; 108(10):3187-3193. PubMed ID: 31226425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analytical Methodologies to Detect N-Nitrosamine Impurities in Active Pharmaceutical Ingredients, Drug Products and Other Matrices.
    Manchuri KM; Shaik MA; Gopireddy VSR; Naziya Sultana ; Gogineni S
    Chem Res Toxicol; 2024 Sep; 37(9):1456-1483. PubMed ID: 39158368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous determination of 13 nitrosamine impurities in biological medicines using salting-out liquid-liquid extraction coupled with liquid chromatography tandem mass spectrometry.
    Luo F; Liu Y; Xie Y; Hou W; Zhang L; Zhang Z
    J Pharm Biomed Anal; 2022 Sep; 218():114867. PubMed ID: 35679708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid Quantitation of Four Nitrosamine Impurities in Angiotensin Receptor Blocker Drug Substances.
    Zhang J; Selaya SD; Shakleya D; Mohammad A; Faustino PJ
    J Pharm Sci; 2023 May; 112(5):1246-1254. PubMed ID: 36509171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.